HMGene, Inc. is a biotechnology company organized around novel therapies for metabolic disorders, with a primary focus on obesity. HMGeneâs approach has been centered on the biology of the fat cell (adipocyte) as an entry for intervention. Using a proprietary platform, HMGene successfully identified molecular targets and drug candidates for obesity therapy and selected targets validated through the generation of proprietary, genetically-modified mice. The company evaluated a preclinical biotherapeutic protein drug candidate for obesity. HMGene's small-molecule drug discovery program against validated targets was designed to generate lead compounds being co-developed with large pharmaceutical companies into commercially-marketed drugs. HMGeneâs devloped method for the elucidation of molecular targets for obesity and the validation of these targets in whole mammals, in conjunction with a strong intellectual property position, lays a firm foundation for novel drug discovery and developm
